Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 36 of 68 of this archive, newest first.
Reported from the analysis, not from a warning notice.
The document is four pages. Three of them are about dates.
A proper account of an operation that existed, and of what closing it cost.
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
The regain trajectories, arm by arm, with the estimands named.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
The route did not close because of a rule about peptides.
Half-life, accumulation ratio and time to steady state are three separate quantities, and confusing them produces most of the bad advice in circulation.
Regain begins immediately, proceeds at a decelerating rate, and does not usually return to baseline within the observed follow-up. Each of those three clauses matters.
The masking phenomenon known as low endotoxin recovery means a formulation can return a clean result while containing endotoxin the assay cannot see.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Efficacy was never the question in this appraisal. Duration of treatment was.
The observation that closes a facility is rarely the dramatic one.
The document is four pages. Three of them are about dates.
The interval between manufacture and analysis is the most under-read figure on the page, and the one most likely to matter by the time a vial is opened.
The evidence base is thin and the document says so, which is to its credit.
Reported from the sessions, and from the two hours afterwards.
Reported from the analysis, not from a warning notice.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the pharmacokinetic data supports about dose timing, missed doses and interruption.
Nausea and gastric delay attenuate over weeks at an unchanged dose. That single physiological fact is the entire justification for holding.
Weight reduction in the long programmes flattens at roughly sixty to seventy-two weeks. The timing is consistent, predictable and almost never mentioned in advance.
The observation that closes a facility is rarely the dramatic one.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
We have catalogued what readers report, ranked by the size of the dosing error each produces.
The route did not close because of a rule about peptides.